Hyperandrogenism, disturbance of the hypothalamus-pituitary-ovary axis followed by elevated serum luteinizing hormone (LH) levels, and insulin resistance are involved in the complicated pathophysiology of polycystic ovary syndrome (PCOS). Kisspeptin is coexpressed with neurokinin B (NKB) in the arcuate nucleus (ARC), the center of the gonadotropin-releasing hormone pulse generator that is responsible for pulsatile LH secretion. We compared 2 androgenized rat models of PCOS to evaluate the estrous cycle, hormonal profiles, and expression of kisspeptin and NKB in the ARC. Rats in our postnatal dihydrotestosterone (DHT)-treatment model exhibited weight gain and persistent diestrus with normal LH levels. In contrast, irregular cycles, with elevated LH serum levels and normal body weight, were found in the prenatally DHT-treated rats. We also found increased signals of kisspeptin and NKB in the ARC of the prenatally DHT-treated rats, and not in the postnatally DHT-treated rats. Our results suggest that prenatal exposure to androgens may result in higher kisspeptin and NKB levels in the ARC, which could be associated with 1 phenotype of PCOS that is characterized by normal body weight and higher LH secretion, whereas in postnatally DHTtreated rats, characteristics such as weight gain and normal LH levels are seen in the obese PCOS phenotype. (Endocrinology 158: 367-377, 2017) K ISS1, the gene encoding kisspeptin, was originally discovered as a suppressor of metastasis in human malignant melanoma in 1996 (1). Ohtaki et al. (2) and Muir et al. (3) afterward demonstrated that kisspeptin is a ligand for an orphan receptor, G-protein coupled receptor 54 (GPR54), in rats and humans. However, the physiological function of kisspeptin in the central nervous system was not revealed until 2003. Seminara et al. (4) found that mutations in GPR54 resulted in hypogonadotropic hypogonadism in humans and mice. It was then revealed that kisspeptin stimulates gonadotropinreleasing hormone (GnRH) secretion via GPR54 expressed by GnRH neurons. Since then, kisspeptin has been considered to play an important role in the onset of puberty and reproductive function.
K ISS1, the gene encoding kisspeptin, was originally discovered as a suppressor of metastasis in human malignant melanoma in 1996 (1). Ohtaki et al. (2) and Muir et al. (3) afterward demonstrated that kisspeptin is a ligand for an orphan receptor, G-protein coupled receptor 54 (GPR54), in rats and humans. However, the physiological function of kisspeptin in the central nervous system was not revealed until 2003. Seminara et al. (4) found that mutations in GPR54 resulted in hypogonadotropic hypogonadism in humans and mice. It was then revealed that kisspeptin stimulates gonadotropinreleasing hormone (GnRH) secretion via GPR54 expressed by GnRH neurons. Since then, kisspeptin has been considered to play an important role in the onset of puberty and reproductive function.
In the rodent hypothalamus, kisspeptin neurons are located in the arcuate (ARC) and anteroventral periventricular (AVPV) nuclei (5, 6) . Several studies have demonstrated that kisspeptin neurons in the ARC and AVPV express sex steroid receptors and transmit negative and positive feedback regulation. Accumulating evidence indicates that kisspeptin neurons in the ARC are involved in the GnRH/luteinizing hormone (LH) pulse generation in a negative feedback manner, whereas kisspeptin neurons in the AVPV are targets of estrogen positive feedback and are therefore involved in preovulatory GnRH/LH surge generation (5) (6) (7) . In addition, recent findings have shown that kisspeptin neurons in the ARC coexpress 2 neuropeptides, dynorphin A (Dyn) and neurokinin B (NKB). Several studies have revealed that secretion of kisspeptin is stimulated and inhibited by NKB and Dyn, respectively (8) . Because of their functional relevance, neurons coexpressing kisspeptin, NKB, and Dyn were termed KNDy neurons.
Polycystic ovary syndrome (PCOS) is a common endocrine disorder of women that affects 5% to 10% of women of reproductive age. PCOS is characterized by polycystic ovaries, ovulatory dysfunction, hyperandrogenism, and elevated LH serum levels. In addition, patients with PCOS often demonstrate metabolic abnormalities, such as insulin resistance and obesity (9, 10) . PCOS is 1 of the leading causes of human infertility and is associated with major health problems. As a result, for decades, there has been extensive discussion about the pathogenesis of PCOS. However, despite wide-ranging approaches to investigating its pathophysiology, PCOS is still not fully understood.
PCOS is a complicated systemic disease involving reproductive and metabolic disturbance. Therefore, many researchers have tried to generate practical animal models of PCOS, and various models have been previously described (11) . Given that androgen excess early in life has been suggested as a cause of polycystic ovaries in adulthood, animal models treated peripubertally with androgens, such as testosterone and dihydrotestosterone (DHT), have been developed. Prepubertal animals that undergo DHT treatment can be induced into presenting features of PCOS, including acyclicity, more atypical follicles, and the major metabolic characteristics of obesity and insulin resistance (12, 13) . On the other hand, offspring derived from prenatally DHT-treated animals have been demonstrated to have reduced fertility and irregular estrous cycles (14, 15) . Studies using prenatally androgenized animals demonstrated impaired estradiol negative feedback regulation (14, (16) (17) (18) , which might be implicated in an increase in basal LH levels and pulse frequency in patients with PCOS. Because kisspeptin neurons in the ARC regulate GnRH/LH pulse generation through the negative feedback of sex steroids, kisspeptin, along with NKB and Dyn, is likely to be involved in the possible disturbance of the negative feedback loop in PCOS. However, few studies have evaluated the levels of kisspeptin, NKB, Dyn, and sex steroid receptors in the ARC of human or animal models.
In the current study, we generated prenatally and postnatally DHT-treated rats as animal models of PCOS, and compared the PCOS phenotype and expression levels of kisspeptin and its related molecules, including sex steroid receptors, in the ARC. We then investigated the mechanism that causes negative feedback impairments and the pathophysiology of PCOS, focusing on the hypothalamic-pituitary-ovarian axis.
Materials and Methods

Animals
Female Wistar rats, both pregnant and at postnatal day (PND) 14, were purchased from Charles River Japan (Shiga, Japan) and administered DHT, as described later. All animals were maintained under a 12-hour light/dark cycle (lights on at 9:00 AM) at 20°C to 25°C with food (CE-2; CLEA Japan, Tokyo, Japan) and water available ad libitum.
Pregnant dams were subcutaneously injected with DHT (3 mg/body/d) or vehicle (40 mL 100% ethanol and 160 mL sesame oil) on the 16th to 19th gestational day, and any female offspring were analyzed as the prenatally DHT-treated rat models of PCOS (n = 12) and prenatal control rats (n = 11), respectively.
At PND 21, rats were administered subcutaneous DHT pellets (7.5 mg/pellet, 90-day release, Innovative Research of America, Sarasota, FL) or placebo pellets, as previously described by Mannerås et al. (12) . Each pup was anesthetized under inhaled isoflurane and given a subscapular subcutaneous pellet implant. DHT-treated rats were used as the postnatally DHT-treated rat models of PCOS (n = 10), and placebo-treated rats were used as the postnatal controls (n = 10). All protocols were approved by the animal experiment committee of Nagoya University Graduate School of Medicine. The care and use of rats were carried out in accordance with the guidelines of the animal experiment committee of Nagoya University Graduate School of Medicine and relevant guidelines and regulations.
Assessment of body weight and estrous cyclicity
The total body weights of both model and control rats were measured every week, starting at PND 21, until they were euthanized. Vaginal smears of model and control rats were checked daily from PND 56 (all animals underwent vaginal opening by PND 35) to assess estrous cyclicity until they were euthanized. Vaginal smear cells from each animal were viewed and determined as diestrus, proestrus, or estrus, based on the shape and density of the cells, as has been previously described (19, 20) .
Collection of blood and soft tissue samples
All rats were euthanized while under isoflurane anesthesia at diestrus from PND 98 to 112. Blood samples were immediately collected from the heart through needle aspiration. Serum was isolated by centrifugation at 3000 g for 10 minutes and stored at 280°C until measurement. After perfusion of 4% paraformaldehyde in 0.05 M phosphate-buffered saline (PBS), the brain and ovaries were removed. Brains were soaked in 4% paraformaldehyde overnight and then transferred to 30% sucrose/0.05 M PBS. Coronal sections (50 mm in thickness), including the ARC-median eminence region, were cut with a cryostat, collected in cryoprotectant solution, and stored at 220°C for immunohistochemistry purpose (21) . Ovaries were fixed in 10% formalin and embedded in paraffin.
Hormonal measurements
Concentrations of LH, follicle-stimulating hormone (FSH), estradiol, progesterone, and testosterone were measured using enzyme-linked immunosorbent assay kits (LH and FSH: Shibayagi, Gunma, Japan) and electrochemiluminescence immunoassay kits (Arkitect Estradiol; Abbott Japan, Chiba, Japan; EClusys Progesterone and EClusys Testosterone; Roche Diagnostics, Tokyo, Japan). The coefficient of variation (with analytical ranges) for LH and FSH were , 5% (0.313 to 10 ng/mL), and , 3% (0.4 to 20 ng/mL), respectively. The coefficients of variation (with analytical ranges) for estradiol, progesterone, and testosterone were , 20% (10 to 1000 pg/mL), , 10% (0.03 to 60 ng/mL), and , 10% (0.25 to 15 ng/mL), respectively.
Ovarian morphologic analysis
Paraffin-embedded ovarian tissue was sliced into 6-mm sections, mounted on SuperFrost glass microscope slides (S9444; Matsunami Glass Industries, Kishiwada, Osaka, Japan), and stained with hematoxylin and eosin. Follicles were classified as follows: preantral follicles (oocyte with 2 to 5 layers of cuboidal granulosa cells), small antral (oocyte surrounded with more than 5 layers of granulosa cells, and/or 1 or 2 small areas of follicular fluid), large antral follicles (contained a single large antral cavity), preovulatory follicles (possessed a single large antrum and an oocyte surrounded by cumulus cells at the end of a stalk of mural granulosa cells), and atretic cystlike follicles (large fluid-filled cyst with an attenuated granulosa cell layer and dispersed theca cell layer) (22, 23) .
Immunohistochemistry of kisspeptin, NKB, estrogen receptor a, and progesterone receptor Coronal brain sections representing the rostral, middle, and caudal regions of the ARC were chosen from each rat, washed with 0.05 M PBS, and mounted on a glass microscope slide (SuperFrost S9444; Matsunami Glass Industries). For immunohistochemical staining of kisspeptin, sections on the slide were blocked in 0.05 M PBS containing 1% bovine serum albumin (PBS-BSA) for 30 minutes, incubated with a solution containing an antibody to kisspeptin (1:1000 dilution, AB9754; Merck/EMD Millipore, Billerica, MA) in PBS-BSA for 24 hours at 4°C, and treated with a solution containing Alexa Fluor 488-labeled goat anti-rabbit antibody (1:100 dilution, A11008; Thermo Fisher Scientific, Waltham, MA) in PBS for 30 minutes at room temperature. Fluorescence mounting medium (Dako Fluorescent Mounting Medium; Dako North America, Carpinteria, CA) was applied to the section, and a coverslip was carefully applied. For immunohistochemical staining of the estrogen receptor (ER) a (1:400 dilution, sc-7207; Santa Cruz Biotechnology, Dallas, TX), progesterone receptor (PR, 1:400 dilution; Dako North America), and NKB (1:5000 dilution, NB300-201; Novus Biologicals, Littleton, CO), the avidinbiotin immunoperoxidase technique using the Histofine SAB-PO kit (Nichirei, Tokyo, Japan) was performed. For double-labeled immunofluorescence of kisspeptin and NKB, sections on the slides were incubated with a solution containing both anti-NKB antibody (1:2000 dilution, NB300-201) and antikisspeptin antibody (1:1000 dilution, sc-18134; Santa Cruz Biotechnology, Dallas, TX) for 24 hours at 4°C and then incubated with Alexa Fluor 568-labeled donkey anti-rabbit antibody (1:200 dilution, ab175692; Abcam, Cambridge, United Kingdom) and Alexa Fluor 488-labeled donkey anti-goat antibody (1:200 dilution, ab150133; Abcam) in PBS for 60 minutes at room temperature. For double-labeled immunofluorescence of kisspeptin and ERa, we used anti-ERa antibodies (sc-7207; Santa Cruz Biotechnology) and anti-kisspeptin antibodies (sc-18134; Santa Cruz Biotechnology) and performed immunofluorescence in the same manner as described earlier (Table 1) . Clear and strong fluorescent signals on cell bodies within the fixed areas of sections containing unilateral ARC or AVPV were considered indicative of immunopositive cells for each molecule. We analyzed the alteration in immunoreactivity of kisspeptin, NKB, ERa, and PR by counting cell signals in 4 
In situ hybridization
We performed in situ hybridization to detect Kiss1 messenger RNA (mRNA) in AVPV, as described previously (5) . Briefly, the sections were washed with PBS, treated with 50 mg/mL proteinase K, and then incubated with 0.25% acetic anhydride in 0.1 M triethanolamine. The sections were hybridized with 1 mg/mL digoxigenin-labeled antisense complementary RNA probes [rat Kiss1 RNA probe for in situ hybridization (Genoestaff, Tokyo, Japan) corresponding to 356 bases of rat Kiss1 mRNA; GenBank accession no. AY196983] or sense complementary RNA probes as a control overnight at 60°C. The sections were washed, immersed in blocking solution, and incubated with an alkaline phosphate-conjugated antidigoxigenin antibody. Finally, the sections were treated with a chromogen solution until a visible signal was detected.
Statistics
Statistically significant differences between groups were determined using the Student t test or the Mann-Whitney U test. The Mann-Whitney U test was applied instead of the Student t test when the variables were not normally distributed. Values are expressed as the mean 6 standard error of the mean (SEM) or the median and all values. A P value of less than 0.05 was considered statistically significant. All analyses were performed using Prism 6.07 Software (GraphPad Software, San Diego, CA).
Results
Body weight, estrous cyclicity, and ovarian morphology
The time course of drug administration and evaluation of phenotypes in prenatally and postnatally DHT-treated rats are illustrated (Fig. 1) . The body weight of postnatally DHT-treated rats increased significantly after 42 days of age, whereas the body weight of prenatally DHT-treated rats did not increase compared with control rats (Fig. 2) . The median ages (with ranges) of vaginal opening were PND 31 (27 to 31), 33 (30 to 33), 31 (28 to 35), and 27.5 (22 to 30) for postnatal control rats, postnatal DHT-treated rats, prenatal control rats, and prenatal DHT-treated rats, respectively. Vaginal opening was significantly early in the prenatal DHT-treated rats (P = 0.015). All control rats showed regular estrous cycles (postnatal control, n = 10; prenatal control, n = 11). In contrast, none of the postnatally or prenatally DHTtreated rats demonstrated a regular cycle. In the postnatally DHT-treated group, 60% (6 of 10) rats showed persistent diestrus. In contrast, in the prenatally DHTtreated group, 9% (1 of 12) rats showed persistent diestrus. Representative cycles of each group are shown in Fig. 2 .
The mass of the ovaries from postnatally DHT-treated rats was significantly lower than in the postnatal control rats [44.30 6 4.54 g vs 72.23 6 5.54 g (mean 6 SEM); P = 0.0009]. In contrast, the mass of the ovaries from prenatally DHT-treated rats and prenatal control rats were not significantly different [76.31 6 2.87 g vs 82.64 6 2.29 g (mean 6 SEM); P = 0.099]. The ovaries of postnatally DHT-treated rats showed fewer small antral follicles and corpora lutea. Moreover, the number of large antral follicles showed a tendency toward decreasing, although there was no significant difference (Fig. 2) . Prenatally DHT-treated rats exhibited multicystic ovaries. Follicle counting revealed a significant increase of atretic cystlike follicles. On the other hand, the number of large antral follicles and preovulatory follicles were decreased compared with the controls.
Assessment of serum gonadotropin and sex steroids
Gonadotropin and sex steroid levels were determined at diestrus. Serum LH levels of postnatally DHT-treated rats were not significantly different from postnatal control rats. In contrast, serum LH levels of prenatally DHT-treated rats were significantly higher than prenatal control rats. No significant differences were found in the serum FSH levels between test rats and their respective controls in either prenatally or postnatally DHT-treated groups (Fig. 3) . Serum progesterone levels of postnatally DHT-treated rats were significantly lower than placebo control rats. In contrast, serum progesterone levels of 
(Student t test). (B)
Representative estrous cycles. Postnatally DHT-treated rats mostly showed persistent diestrus (upper panel), whereas prenatally DHT-treated rats mostly exhibited irregular cycles. E, P, and D represent estrus, proestrus, and diestrus, respectively. (C) Morphological appearance and evaluation of follicles in affected ovaries from postnatally (upper panel) and prenatally (lower panel) DHT-treated rats. Both rats showed a significant decrease in the number of corpora lutea (*). Prenatally DHT-treated rats showed a significant increase in atretic cystlike follicles (arrowheads), a trait which corresponds to human PCOS. The bar represents 1 mm. Bar graphs show mean 6 SEM. *1, P , 0.02; *2, P , 0.01; *3, P , 0.05 (Mann-Whitney U test). press.endocrine.org/journal/endoprenatally DHT-treated rats tended to be lower than those of prenatal control rats, although there was no significant difference. No significant differences were found in the serum estradiol or testosterone levels between DHT-treated rats and control rats in either prenatal or postnatal groups (Fig. 3) .
Immunoreactivity of peptides and sex steroid receptors in ARC and AVPV Because serum LH levels were increased in the prenatally DHT-treated rats, we evaluated immunoreactivity of kisspeptin in the ARC. Postnatally DHT-treated rats showed rather small numbers of kisspeptin-immunoreactive cell bodies in the rostral and middle ARC. However, there was no significant difference compared with postnatal control rats. In contrast, the number of kisspeptinimmunoreactive cell bodies increased significantly in the rostral and middle ARC of prenatally DHT-treated rats compared with prenatal control rats [ Fig. 4(A) ]. In the KNDy neurons of the rodent ARC, it has been demonstrated that NKB positively regulates kisspeptin secretion (24); therefore, we then evaluated NKB expression in the prenatally DHT-treated rats. The number of NKBpositive cell bodies tended to be decreased in the middle ARC of postnatally DHT-treated rats compared with placebo control rats. In contrast, prenatal DHT treatment increased the number of NKB-positive cell bodies in the middle ARC significantly compared with prenatal control rats [ Fig. 4(B) ]. In addition, double-label immunofluorescence revealed that immunoreactivity for NKB generally overlapped with that of kisspeptin [ Fig. 4(C) ].
Kisspeptin neurons can be regulated by the negative feedback of sex steroids in rodents. Therefore, we next assessed expression of sex steroid receptors in the ARC. However, the numbers of ERa-or PR-positive cell nuclei in the ARC were not significantly different between DHT-treated rats and control rats in either prenatal or postnatal treatment groups [ Fig. 5(A) and 5(B) ]. In this immunofluorescence analysis, we confirmed the colocalization of ERa and kisspeptin [ Fig. 5(C) ].
Kisspeptin neurons in the AVPV are involved in preovulatory GnRH/LH surge generation as targets of estrogen positive feedback. Having found a change in the immunoreactivity of kisspeptin in the ARC of the prenatally DHT-treated rats, we then assessed the immunoreactivity of kisspeptin using immunofluorescence and the expression of Kiss1 mRNA using in situ hybridization in the AVPV. There were no significant differences in kisspeptin immunoreactivity or Kiss1 mRNA expression in the AVPV between the prenatally DHT-treated rats and prenatal controls (Fig. 6 ).
Discussion
Because human PCOS is a systemic disease that includes reproductive and metabolic dysfunction, pathophysiology involving reproductive and metabolic organs has been explored using animal models. Clinical features of human PCOS vary depending on the patient; thus, PCOS has been considered to be a heterogeneous disease with complicated pathogenesis. Therefore, several animal models have been developed for the analytical exploration of PCOS. An androgenized animal model is 1 of the Figure 3 . Measurements of serum concentrations of gonadotropins and sex steroids. There was no significant difference in the serum levels of FSH or LH between postnatally DHT-treated and control rats (upper panel). Serum LH levels were significantly increased in prenatally DHT-treated rats (lower panel) compared with those of controls. Progesterone (P4) levels were significantly decreased in the postnatally DHT-treated rats (upper panel), whereas there was no significant difference in either estradiol (E2), progesterone (P4), or testosterone (T) levels in prenatally DHTtreated rats (lower panel). Bars in each graph represent the median. *P , 0.05 (Mann-Whitney U test).
major PCOS models. However, phenotypes can differ depending on when and what kind of androgens are administered (11, 22) .
In the current study, we created 2 animal models of PCOS by using postnatal or prenatal DHT administration, and compared the physiological traits. The main purpose in the use of the postnatally androgenized model is to evaluate how hyperandrogenism affects reproductive and metabolic function. Our postnatally DHT-treated rats showed increased body weight and ovulatory dysfunction. The morphological changes seen in the ovaries included fewer growing follicles and corpora lutea. The decreased size of the ovary and number of cystic follicles did not correspond to the affected ovaries as seen in human PCOS. Our results are mostly in agreement with previous reports that used similar models (12, 13) . Another discordant trait between human PCOS and our postnatally DHT-treated rats is gonadotropin level. We did not reproduce elevated LH levels and relatively decreased concentrations of FSH in the postnatal DHT rats. However, this was also noted to have happened to a similar model in a previous study (22) .
In contrast, in the prenatally DHT-administered model, the numbers of large antral follicles decreased, whereas atretic cystlike follicles increased. Additionally, these rats presented with irregular estrous cyclicity, as well as decreased numbers of preovulatory follicles and corpora lutea that implied decreased ovulations. These findings are consistent with the reproductive features of patients with PCOS. Furthermore, basal serum LH levels were elevated in this model. Moore et al. (14) demonstrated an impairment of the estrogen negative feedback loop followed by an alteration of LH pulsatile secretion, such as elevated firing frequency, in prenatal androgenized mice. The model used by Moore et al. (14) is similar to our prenatally DHT-treated rat model. Therefore, we speculate that consecutive elevation of serum LH following possible alteration of LH pulsatile secretion with relative shortage of FSH stimulation could impair normal folliculogenesis and ovulation. These findings were also consistent with human PCOS. In press.endocrine.org/journal/endocontrast to the postnatally DHT-treated rats, body weight of prenatally DHT-treated rats did not show a significant increase compared with controls. Although PCOS is a heterogeneous disease, we can safely say that PCOS can be classified into 2 subgroups by phenotype. Obesity, a characteristic in 1 of the major phenotypes of PCOS, is not a prerequisite feature and is found in approximately 50% of patients with PCOS (25) . Several studies have reported that obese patients with PCOS show more apparent tendency toward hyperandrogenemia and insulin resistance with relatively normal LH levels, whereas higher LH levels with less insulin resistance are more likely in nonobese patients with PCOS (26) (27) (28) . Morales et al. (29) demonstrated hypersecretion of LH with higher response to GnRH in nonobese patients with PCOS compared with obese patients with PCOS. The phenotypes seen in our postnatal DHT models, such as weight gain, decreased number of small antral follicles, and persistent diestrus, might correspond with the severe hyperandrogenemia and insulin resistance seen in obese patients with PCOS. In contrast, the elevated LH serum level and normal body weight of prenatally DHT-treated rats shown here are in line with findings in nonobese patients with PCOS, as seen more often in patients of Asian ethnicity (30, 31) .
Given that we found the main difference between postnatally and prenatally DHT-treated rats in the gonadotropin-ovarian axis, we analyzed the hypothalamic regulation of gonadotropin secretion. We evaluated the immunoreactivity of kisspeptin in the ARC, which regulates gonadotropin release through the negative feedback of sex steroids. Prenatally DHT-treated rats showed increased kisspeptin immunoreactivity in the ARC compared with controls, whereas no increase in kisspeptin signals was found in the postnatally DHT-treated rats. These findings are consistent with the differing levels of serum LH. Furthermore, NKB, a positive regulator of kisspeptin in KNDy neurons, also demonstrated increased immunoreactivity in the ARC of prenatally DHT-treated rats. We also found a small but significant difference in the period of vaginal opening in the prenatally DHT-treated rats. Alterations in KNDy neurons in ARC and serum LH levels might be implicated in the early onset of vaginal opening in the prenatally DHT-treated rats as a PCOS model. Indeed, it has been prospectively reported that 32% of women who underwent precocious puberty developed PCOS later (32) . Our model might be helpful to understand the relationship between precocious puberty and PCOS. Very recently, we reported that rats treated with a progesterone receptor antagonist, RU-486, exhibit some of the PCOS phenotypes with increased kisspeptin-positive cells in the ARC (33) . A decrease in feedback sensitivity to progesterone of gonadotropic cells in the hypothalamus following LH hypersecretion might be caused by hyperandrogenemia (34) . Taken together, the finding that alterations of KNDy neurons in the hypothalamic ARC affect PCOS phenotypes, especially in nonobese PCOS, is relevant to hyperandrogenemia and the feedback effect of progesterone.
Although the human PCOS phenotype is implicated in the disturbance of the hypothalamus-pituitary-ovary axis responsible for the estrogen negative feedback loop, the preovulatory LH surge can be driven in a positive feedback manner induced by estradiol. Moore et al. (14) demonstrated that estradiol benzoate-treated animals exhibited an LH surge regardless of prenatal DHT treatment. Immunofluorescence labeling of kisspeptin in the AVPV revealed no alteration in immunoreactivity of kisspeptin in the prenatally DHT-treated rats compared with prenatal control rats. Taken together, we speculate that prenatal DHT treatment mainly affects KNDy neurons in the ARC, not the AVPV, and therefore results in hypersecretion of basal LH without impairment of the LH surge. Consequently, disturbance of folliculogenesis may result in fewer corpus luteum.
We hypothesized that alteration of kisspeptin-and NKB-positive cells would be influenced by the expression of sex steroid receptors mediating negative feedback to KNDy neurons. With respect to the regulation of LH pulse frequency, negative feedback of sex steroids is important. Goodman et al. (35) demonstrated that ARC is an important site of progesterone negative feedback in the ewe. We recently reported similar results in the RU486-treated rat model of PCOS. Blockade of progesterone negative feedback led to the alteration of LH pulse frequency in conjunction with an increase in kisspeptin in the ARC (32) . However, we did not find any significant changes in the expression levels of PR or ERa in either group. Because we confirmed the colocalization of ERa in kisspeptin neurons, it is not likely that prenatal treatment with DHT affected colocalization of sex steroid receptors in the KNDy neurons. One possibility is that changes in local sex steroid levels in the ARC could affect the expression of kisspeptin and NKB via a negative feedback loop. However, we did not find significant changes in the serum concentrations of estradiol, progesterone, or testosterone. Another possible explanation for these results is that the changes seen in KNDy neurons in the ARC could primarily occur independently of the feedback of sex steroids.
Some recent studies reported that epigenetic modification, especially altered DNA methylation, could contribute to the pathogenesis of PCOS (36) (37) (38) . DNA methylation is an important epigenetic mechanism that can modify the expression of genes without affecting the DNA sequence. Xu et al. (39) reported the alteration of DNA methylation in adipose tissue of prenatally androgenized female monkeys. Moreover, in human PCOS, evidence of epigenetic alteration in the ovaries, adipose tissues, and blood cells has been presented (36) (37) (38) 40) . Regarding epigenetic modification in the brain, Nugent et al. (19) reported altered DNA methylation in the preoptic area of neonatal androgen-treated mice from the perspective of masculinization. Additionally, epigenetic mechanisms with fetal developmental press.endocrine.org/journal/endoorigins have been well investigated in metabolic diseases such as obesity, hyperlipidemia, and diabetes (41) (42) (43) . Taken together, it is possible that the epigenetic change could be a cause of altered NKB and kisspeptin expression as well as levels in the ARC of our prenatally DHTtreated rats.
In conclusion, we generated 2 different rat models of PCOS using 2 different androgen administration regimens and compared the differences in immunoreactivity of kisspeptin, and its related molecules in the ARC, in association with clinical features of PCOS, including gonadotropin levels. The period of exposure to DHT led to the alteration of kisspeptin immunoreactivity in the ARC, which may have caused the different gonadotropin levels and ovarian morphology. Our results suggest that prenatal androgen excess may result in higher kisspeptin levels in the ARC, which could be associated with 1 phenotype of PCOS that is characterized by normal body weight and higher LH secretion. Further study is required to determine the effect of prenatal exposure to excess androgens on epigenetic alteration.
